|
|
Blood, Vol. 107, Issue 10, 3940-3949, May 15, 2006
In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma
Blood Beyer et al.
107: 3940
Supplemental Table and Figure for : Beyer et al
Files in this Data Supplement:
- Table S1 (PDF, 88.5 KB) -
Patient characteristics
Patient characteristics including gender, age at analysis, Durie and Salmon or Binet stage, first diagnosis, therapy, paraprotein and frequency of Treg cells.
f=female, m=male;
therapy: A=H=Doxorubicin, B=Bendamustine, BMT=autologous bone-marrow transplantation,
Bo=Bortezomib, C=Cyclophosphamide, E=Etoposide,
I=Idarubicin, Ifo=Ifosphamide, M=Melphalan,
O=V=Vincristine, D=P=Prednisone, Th=Thalidomide,
no tx=no therapy
- Figure S1. Proliferation of purified CD4+ T cells from healthy individuals and MM pts (JPG, 51.1 KB)
-
CD4+ T cells purified from PBMC were polyconally activated with PHA, PWM, or anti-CD3 and anti-CD28 mAbs. Proliferation of CD4+ T cells was monitored by measuring BrdU incorporation on day 2-3 of culture. For each experiment, CD4+ T cells from a healthy individual (grey bar) were analyzed under the same experimental conditions as the T cells from MM pts (white bars). Shown here is one representative experiment. Error bars represent standard deviation.
|
|
